Identification of a major radiometabolite of [11C]PBB3.

[1]  Ming-Rong Zhang,et al.  PET Quantification of Tau Pathology in Human Brain with 11C-PBB3 , 2015, The Journal of Nuclear Medicine.

[2]  H. Arai,et al.  [18F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer’s disease , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  Lin Xie,et al.  Radiosynthesis, Photoisomerization, Biodistribution, and Metabolite Analysis of 11C-PBB3 as a Clinically Useful PET Probe for Imaging of Tau Pathology , 2014, The Journal of Nuclear Medicine.

[4]  H. Kolb,et al.  [18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease , 2013, Alzheimer's & Dementia.

[5]  H. Wood.  Alzheimer disease: [11C]PBB3—a new PET ligand that identifies tau pathology in the brains of patients with AD , 2013, Nature Reviews Neurology.

[6]  J. Trojanowski,et al.  Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls , 2013, Neuron.

[7]  H. Arai,et al.  Novel 18F-Labeled Arylquinoline Derivatives for Noninvasive Imaging of Tau Pathology in Alzheimer Disease , 2013, The Journal of Nuclear Medicine.

[8]  Annelaure Damont,et al.  Metabolism and Quantification of [18F]DPA-714, a New TSPO Positron Emission Tomography Radioligand , 2013, Drug Metabolism and Disposition.

[9]  F. Dollé,et al.  Difficulties in dopamine transporter radioligand PET analysis: the example of LBT-999 using [18F] and [11C] labelling: part II: Metabolism studies. , 2012, Nuclear medicine and biology.

[10]  F. Dollé,et al.  Difficulties in dopamine transporter radioligand PET analysis: the example of LBT-999 using [18F] and [11C] labelling Part I: PET studies. , 2012, Nuclear medicine and biology.

[11]  Victor W Pike,et al.  PET radiotracers: crossing the blood-brain barrier and surviving metabolism. , 2009, Trends in pharmacological sciences.

[12]  J. Trojanowski,et al.  Tau-mediated neurodegeneration in Alzheimer's disease and related disorders , 2007, Nature Reviews Neuroscience.

[13]  A. Kong,et al.  Induction of phase I, II and III drug metabolism/transport by xenobiotics , 2005, Archives of pharmacal research.

[14]  Jos H Beijnen,et al.  An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons. , 2003, Toxicology and applied pharmacology.

[15]  M. Takei,et al.  Sensitive measurement of positron emitters eluted from HPLC. , 2001, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[16]  S. Tannenbaum,et al.  Sulfotransferase-mediated activation of 4-hydroxy- and 3,4-dihydroxy-3,4-dihydrocyclopenta[c,d]pyrene, major metabolites of cyclopenta[c,d]pyrene. , 1993, Cancer research.

[17]  Min-Ying Su,et al.  Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. , 2014, Journal of Alzheimer's disease : JAD.

[18]  K. Tetsuka,et al.  Quantitative prediction of intestinal glucuronidation of drugs in rats using in vitro metabolic clearance data. , 2012, Drug metabolism and pharmacokinetics.